<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577313</url>
  </required_header>
  <id_info>
    <org_study_id>H19-161</org_study_id>
    <secondary_id>R01MH121129</secondary_id>
    <nct_id>NCT04577313</nct_id>
  </id_info>
  <brief_title>HIV Treatment Adherence Dose Determination Trial</brief_title>
  <official_title>DOSE DETERMINATION TRIAL: The Start/Persist Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research will conduct the first dose-determination trial to find the optimal&#xD;
      number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV&#xD;
      treatment adherence. The results of this study will determine how much intervention is needed&#xD;
      for whom and at what cost to guide health policy and implementation of behavioral&#xD;
      interventions designed to improve durable viral suppression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research will conduct the first ever dose-determination trial of a behavioral&#xD;
      intervention to improve engagement in HIV care, antiretroviral therapy (ART) adherence and&#xD;
      HIV viral suppression. The trial is designed to inform the implementation of behavioral&#xD;
      interventions, including several in CDC's Compendium of Evidence-Based Interventions.&#xD;
      Behavioral counseling has the flexibility and reach to overcome numerous challenges to HIV&#xD;
      care, including social, emotional, and structural barriers. However, basic questions of how&#xD;
      to best implement and scale-up interventions remain unanswered, such as &quot;how much&#xD;
      intervention is needed to achieve HIV suppression in subgroups of patients facing individual&#xD;
      and social challenges?&quot; There are currently no dose-determination trials in the HIV&#xD;
      behavioral intervention literature to guide implementation decisions and health service&#xD;
      policy. In the proposed research the investigators specifically aim to: (a) determine the&#xD;
      minimum effective dose of an evidence-based HIV treatment engagement and adherence&#xD;
      intervention, (b) identify subgroups of patients requiring greater and fewer intervention&#xD;
      resources to achieve and sustain viral suppression, and (c) the costs associated with&#xD;
      intervention dose-response. Participants who are receiving ART with empirically determined&#xD;
      low-adherence will be randomized to either: (a) the dose determination condition of weekly&#xD;
      evidence-based behavioral self-regulation counseling until achieving HIV suppression or (b)&#xD;
      fixed dose 5-weekly sessions of evidence-based behavioral self-regulation counseling&#xD;
      sessions. The dose determination condition adjusts to patient needs and determines the dose&#xD;
      to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that&#xD;
      does not adjust to patient response. The trial is therefore designed to determine the number&#xD;
      of behavioral counseling intervention sessions needed to achieve and sustain HIV suppression.&#xD;
      Once meeting criteria for adherence / viral suppressed, counseling in the dose-determination&#xD;
      condition is suspended. In contrast, the fixed-dose condition is delivered in five prescribed&#xD;
      sessions as disseminated by the CDC. Follow-up assessments commence for 12-months from&#xD;
      baseline with the primary endpoint of 12-month blood plasma HIV viral load and secondary&#xD;
      outcome of ART adherence. Response to counseling is defined by achieving viral suppression&#xD;
      and non-response is defined by not achieving optimal adherence / viral suppression.&#xD;
      Participants in both the dose-determination and fixed-session conditions who initially&#xD;
      respond and rebound to unsuppressed viral load will receive additional counseling with&#xD;
      redose-response monitored and analyzed. Longitudinal analyses will examine intervention dose&#xD;
      for key patient subgroups and dose-response cost-effectiveness analyses to guide resource&#xD;
      allocation and implementation decisions. This research is aimed at informing health policy&#xD;
      makers and programmatic decisions regarding intervention implementation to increase the&#xD;
      likelihood of sustained HIV suppression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Antiretroviral Therapy Adherence from Baseline to 12-Months</measure>
    <time_frame>12-Month</time_frame>
    <description>Medication adherence defined by percentage of medication doses taken as prescribed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HIV Viral Load from Baseline to 12-months</measure>
    <time_frame>12-months</time_frame>
    <description>Blood plasma HIV RNA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Continuous Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Self-Regulation Adherence Counseling</intervention_name>
    <description>Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.</description>
    <arm_group_label>Continuous Counseling</arm_group_label>
    <arm_group_label>Fixed Counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed HIV positive&#xD;
&#xD;
          -  Confirmed prescribed antiretroviral therapy&#xD;
&#xD;
          -  Confirmed non-adherent to anti-retroviral therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not have access to a phone&#xD;
&#xD;
          -  Does not have access to the internet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seth Kalichman, PhD</last_name>
    <phone>860 208 3706</phone>
    <email>seth.k@uconn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Kalichman, PhD</last_name>
      <phone>860-208-3706</phone>
      <email>seth.k@uconn.edu</email>
    </contact>
    <investigator>
      <last_name>Seth Kalichman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Field Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Kalichman, PhD</last_name>
      <phone>860-208-3706</phone>
      <email>seth.k@uconn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kalichman SC, Kalichman MO, Cherry C, Eaton LA, Cruess D, Schinazi RF. Randomized Factorial Trial of Phone-Delivered Support Counseling and Daily Text Message Reminders for HIV Treatment Adherence. J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):47-54. doi: 10.1097/QAI.0000000000001020.</citation>
    <PMID>27105048</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Seth Kalichman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sets masked for all patient level identifying information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

